Introduction
============

Anal cancer is a rare tumour of the gastrointestinal tract representing only about 2% of the anorectal malignancies \[[@B1]\]. Most common anal cancers are squamous cell carcinomas and adenocarcinomas. Less common ones are basaloid carcinoma, melanoma, leiomyosarcoma and small cell carcinoma \[[@B1]\]. The latter, though very rare, is clinically important because of its aggressive clinical course with a tendency for early distant metastases. Small cell carcinomas of the anus are oncologically similar to their counterparts in the lungs and are therefore treated along the same lines.

Case presentation
=================

A 60-year old African lady originally from Ghana presented with a short history of rectal bleeding and anal pain. Over the past three months, she had noticed tenesmus and increased frequency of bowel movements, as well as anorexia and weight loss. There was no significant past or family history. She was a non-smoker. On rectal examination there was a palpable mass which bled on contact. There were no clinical features of bowel obstruction. An MRI of the anus showed a 2.7 cm tumour in the posterior aspect of the distal anal canal (Figure [1](#F1){ref-type="fig"}). At examination under anaesthetic (EUA) the mass in the anus was confirmed and biopsies were taken. The histopathology showed small malignant cells with hyperchromatic nuclei and scanty cytoplasm on haematoxylin and eosin staining (Figure [2](#F2){ref-type="fig"}). On immunostaining, the malignant cells were strongly positive for CD56 (Figure [3](#F3){ref-type="fig"}) and showed weak focal positivity for CAM 5.2 and MNF. There was negative staining for CK7, CK20, thyroid transcription factor 1 (TTF-1) and leukocyte common antigen. These results were consistent with a primary small cell carcinoma of the anus. The patient was not tested for HIV and tumour markers were not measured. Staging CT and PET scans showed no evidence of metastatic disease. The patient underwent treatment with six cycles of chemotherapy using cisplatinum and etoposide followed by a course of radical radiotherapy to the anus and pelvis. Following treatment there was thickening at the primary tumour site; however two EUA\'s and biopsies did not show any residual tumour. Twelve months after completion of treatment the patient relapsed with liver and lung metastasis although the primary site remained clear. No response was seen to palliative chemotherapy and the patient succumbed to metastatic disease 18 months following the initial diagnosis.

![**MRI of the anal canal showing the tumour**.](1757-1626-2-9396-1){#F1}

![**Haematoxylin and eosin staining of the small cell carcinoma of the anus**.](1757-1626-2-9396-2){#F2}

![**Immunohistochemical staining of the small cell carcinoma of the anus**.](1757-1626-2-9396-3){#F3}

Discussion
==========

Small-cell carcinoma of the lungs, first described in 1926, accounts for about 20% of all lung cancers whereas extra-pulmonary small cell carcinomas are uncommon, with an incidence of approximately 0.4% \[[@B2]\]. Approximately 544 cases of gastro-intestinal small cell carcinomas were reported in the English literature till 2004 \[[@B3]\]. The oesophagus is the most common primary site followed by colorectal \[[@B4]\].

Less than 1% of anal cancers are small cell carcinomas-the most common being squamous cell carcinomas (74%) and 19% are adenocarcinomas \[[@B5]\].

These tumours have been documented in HIV positive patients, and those with a history of exposure to radiation \[[@B6]\]. Neuroendocrine (NE) tumours can be found incidentally within adenomatous polyps \[[@B7],[@B8]\]. To diagnose small cell carcinoma, positive immuno-reactivity to neuroendocrine markers is required-the most reliable being synaptophysin \[[@B9]\]. Other markers include CD56 and Leu-7/CD57. CD56 is a neural cell adhesion molecule that is positive in small cell carcinomas of different sites including the lung and gastrointestinal tract. The use of thyroid transcription factor (TTF)-1 will help separate a primary anal canal small cell carcinoma from a lung metastasis, as it is positive in the latter. Systemic symptoms are common; ectopic hormonal secretion may occur.

These tumours are highly aggressive, with lymph node, liver and lung metastasis at presentation even when the primary tumour is limited to the submucosa or mucosa \[[@B10]\]. Metastatic disease was detected at the time of diagnosis in 69% percent of the patients in the study by Bernick et al \[[@B9]\]. The 6-month survival is 58% and 5-year survival is 6% \[[@B11]\]. In contrast, for squamous cell carcinoma of the anus, the overall survival rate for advanced tumours is 50-60% at 5 years \[[@B12]\]. In anal small cell carcinoma with or without metastatic disease at presentation, chemotherapy is the main modality of treatment. It is Cisplatinum-based and usually includes etoposide, cyclophosphamide and doxorubicin. Radiotherapy is mainly for local control and relief of symptoms \[[@B1]\]. The response to chemotherapy is 70% to 90% though transient. Typically, a good response to initial therapy is shortly followed by relapse or rapid progression with a median survival of only 6-12 months \[[@B1]\]. Though our patient did not present with distant metastasis, she developed lung and liver secondaries a year after completion of treatment. At this stage there was no local recurrence. Her clinical course matched what has been described in previous case reports.

Conclusion
==========

Small cell carcinoma of the anus is very rare. Immunocytochemistry is needed for diagnosis. Chemotherapy is the mainstay of treatment even though the response is short lived. Radiotherapy is mainly for local control and relief of symptoms. The prognosis is poor with frequent early distant metastasis despite local control.
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